Cryo-Cell International, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Description of Business and Summary of Significant Accounting Policies (Tables)

Description of Business and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Nov. 30, 2017

Estimated Useful Lives of Property and Equipment

Estimated useful lives of property and equipment are as follows:


Furniture and equipment		3-10 years
Leasehold improvements		Lesser of 8-10 years or the lives of the leases
Computer software – internal use		1-5 years

Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of November 30, 2017 and 2016, respectively, segregated among the appropriate levels within the fair value hierarchy:


	Fair Value at November 30, 2017		Fair Value Measurements at November 30, 2017 Using
Description	Fair Value at November 30, 2017		Level 1		Level 2		Level 3
Assets:
Trading securities	$	96,600	$	96,600		—		—
Available-for-sale securities		342,722		342,722		—		—

Total	$	439,322	$	439,322		—		—


	Fair Value at November 30, 2016		Fair Value Measurements at November 30, 2016 Using
Description	Fair Value at November 30, 2016		Level 1		Level 2		Level 3
Assets:
Trading securities	$	304,142	$	304,142		—		—
Available-for-sale securities		320,081		320,081		—		—

Total	$	624,223	$	624,223		—		—

Calculation of Basic and Diluted Net Income (Loss) per Common Share

The composition of basic and diluted net income (loss) per share is as follows:


		November 30, 2017		November 30, 2016
Numerator:
Net income (loss)	$	2,315,100	($	1,320,800	)
Denominator:
Weighted-average shares outstanding-basic		7,062,870		8,112,791
Dilutive common shares issuable upon exercise of stock options		590,114		—

Weighted-average shares-diluted		7,652,984		8,112,791

Income (loss) per share:
Basic	$	0.33	($	0.16	)

Diluted	$	0.30	($	0.16	)